{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:32:33Z","timestamp":1786635153378,"version":"build-2736575974"},"reference-count":108,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To highlight key factors required to optimize multi\u2010mechanistic approaches with oral combination treatments for the acute management of a migraine attack.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Given the complex multi\u2010factorial nature of migraine, combining treatments with different mechanisms of action should improve outcomes compared to monotherapies, but this has not been demonstrated with all treatment combinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>For this narrative review, we searched PubMed using combinations of these terms: migraine, acute treatment, combination therapy, fixed\u2010dose combination therapy, multi\u2010mechanistic treatment, pharmacokinetics, and pharmacodynamics. All articles considered relevant were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>None of the existing migraine acute treatments as monotherapy effectively treat the key pathophysiological processes of migraine completely. Many patients do not achieve 2\u2010h pain freedom, which is key to avoiding migraine recurrence, medication overuse leading to chronification, and migraine\u2010related disability. The development of combination approaches has led to only two combinations with demonstrated superiority over their individual components: aspirin\/acetaminophen\/caffeine and sumatriptan\/naproxen sodium. The latter is the most effective proven combination treatment because it targets peripheral activation of central pain pathways during the early migraine stages and central sensitization that develops later, independent of peripheral input. Other triptan\/nonsteroidal anti\u2010inflammatory drug combinations with higher efficacy as monotherapies could be more effective than sumatriptan\/naproxen sodium, particularly if their pharmacokinetic profiles align with the vasoactive mediators of peripheral and central sensitization that they target.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Combination treatments with different mechanisms of action targeting key distinct pathophysiological processes of migraine may be more effective than monotherapies, particularly if their pharmacokinetic profiles are optimized to target those processes at the right time. Further research in this area is warranted.<\/jats:p>\n                    <jats:p>\n                      <jats:boxed-text content-type=\"graphic\" position=\"anchor\">\n                        <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/head70051-gra-0001-m.png\">\n                          <jats:alt-text>image<\/jats:alt-text>\n                        <\/jats:graphic>\n                      <\/jats:boxed-text>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.70051","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T16:36:25Z","timestamp":1772987785000},"page":"1181-1192","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel optimization of multi\u2010mechanistic approaches for the acute treatment of a migraine attack: A review"],"prefix":"10.1111","volume":"66","author":[{"given":"Stephen","family":"Silberstein","sequence":"first","affiliation":[{"name":"Jefferson Headache Center Thomas Jefferson University  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan M.","family":"Rapoport","sequence":"additional","affiliation":[{"name":"The David Geffen School of Medicine at UCLA  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30322-3"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102412441717"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30435-0"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn321"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2015"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.831035"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30185-1"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.07.021"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2016.06.012"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00892.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13529"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.13.1443"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2013.10.010"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414523846"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.3233\/VES-2012-0433"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13300"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.03.001"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2006.01130.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/JXX.0000000000000397"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01494-9"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01110-9"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.11.004"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010657"},{"issue":"1","key":"e_1_2_9_25_1","first-page":"S13","article-title":"Migraine\u2010related disability: impact and implications for sufferers' lives and clinical issues","volume":"56","author":"Holmes WF","year":"2001","journal-title":"Neurology"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519090-00004"},{"issue":"4","key":"e_1_2_9_27_1","article-title":"Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults","volume":"4","author":"Law S","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420963857"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12550"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/2514183X18823377"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241252666"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.02.004"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph3061966"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.937704"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/11635440-000000000-00000"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2012.05.003"},{"key":"e_1_2_9_37_1","first-page":"120","article-title":"Antinociceptive tolerance to NSAIDs partially mediated via endocannabinoids in anterior cinculate cortex of rats","volume":"280","author":"Tsagareli N","year":"2018","journal-title":"Georgian Med News"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080107"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"issue":"4","key":"e_1_2_9_40_1","article-title":"Effects of non\u2010steroidal anti\u2010inflammatory drugs (NSAIDs) and gastroprotective NSAIDs on the gastrointestinal tract: a narrative review","volume":"15","author":"Sohail R","year":"2023","journal-title":"Cureus"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319300"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.580289"},{"issue":"4","key":"e_1_2_9_43_1","first-page":"243","article-title":"Acute migraine headache: treatment strategies","volume":"97","author":"Mayans L","year":"2018","journal-title":"Am Fam Physician"},{"key":"e_1_2_9_44_1","unstructured":"Johnson & Johnson Inc.TYLENOL\u00ae (Acetaminophen) Full Prescribing Information;2021. Accessed October 29 2025.https:\/\/pdf.hres.ca\/dpd_pm\/00062135.PDF"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0592-1"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2013.827472"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0306147101"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.01.005"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-006-0586-y"},{"key":"e_1_2_9_50_1","unstructured":"Merck Sharp & Dohme Corp.MAXALT (Rizatriptan Benzoate) Highlights of Prescribing Information;2011. Accessed December 12 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020864s011s016s017s018s019 020865s012s016s018s020s021lbl.pdf"},{"key":"e_1_2_9_51_1","unstructured":"GlaxoSmithKline.IMITREX (Sumatriptan Succinate) Highlights of Prescribing Information;2013. Accessed December 12 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020132s028 020626s025lbl.pdf"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418768095"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2020.100053"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2019.1618830"},{"key":"e_1_2_9_55_1","unstructured":"AbbVie Inc.UBRELVY\u00ae (Ubrogepant) Highlights of Prescribing Information;2025. Accessed May 1 2025.https:\/\/www.rxabbvie.com\/pdf\/ubrelvy_pi.pdf"},{"key":"e_1_2_9_56_1","unstructured":"Pfizer Inc.NURTEC\u00ae ODT (Rimegepant) Highlights of Prescribing Information;2025. Accessed May 1 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/212728s026lbl.pdf"},{"key":"e_1_2_9_57_1","unstructured":"Pfizer Inc.ZAVPRET\u2122 (Zavegepant) Highlights of Prescribing Information;2025. Accessed May 1 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/216386s005lbl.pdf"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-022-00388-8"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01138-x"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01132-3"},{"key":"e_1_2_9_61_1","unstructured":"Ely Lilly and Co.REYVOW\u00ae (Lasmiditan) Highlights of Prescribing Informatiton;2022. Accessed October 29 2025.https:\/\/pi.lilly.com\/us\/reyvow\u2010uspi.pdf"},{"key":"e_1_2_9_62_1","unstructured":"National Center for Biotechnology Information.PubChem Compound Summary for CID 11610526 Lasmiditan;2025. Accessed March 14 2025.https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Lasmiditan"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12499"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31828aab14"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000806"},{"key":"e_1_2_9_66_1","unstructured":"FDA.Migraine: Developing Drugs for Acute Treatment: Guidance for Industry;2018. Accessed January 29 2025.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/migraine\u2010developing\u2010drugs\u2010acute\u2010treatment"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-02203"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410385585"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419859313"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01303-w"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.787980"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420941827"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102409354390"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2002.02016.x"},{"issue":"22","key":"e_1_2_9_75_1","first-page":"365","article-title":"Chronic headache due to overuse of analgesics and anti\u2010migraine agents","volume":"115","author":"Diener HC","year":"2018","journal-title":"Dtsch Arztebl Int"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S329280"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13034"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2019.07.006"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-005-0004-5"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1249223"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2009.02029.x"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.4103\/0972-2327.99998"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00602.x"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.05107.x"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-4-4"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15103"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.2147\/nedt.2006.2.3.293"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2005.00948.x"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2014.03.2743"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.02039.x"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01806.x"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2009.01458.x"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000316800.22949.20"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.05178.x"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-03095"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-02034"},{"issue":"2","key":"e_1_2_9_97_1","doi-asserted-by":"crossref","DOI":"10.1177\/03331024221143773","article-title":"Place of next generation acute migraine specific treatments among triptans, non\u2010responders and contraindications to triptans and possible combination therapies","volume":"43","author":"Boer I","year":"2023","journal-title":"Cephalalgia"},{"key":"e_1_2_9_98_1","unstructured":"Currax Pharmaceuticals LLC.TREXIMET (Sumatriptan and Naproxen Sodium) Highlights of Prescribing Information;2021. Accessed December 12 2024.https:\/\/www.treximet.com\/wp\u2010content\/themes\/Treximet\/pdf\/prescribing\u2010information.pdf"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16434"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2000.00146.x"},{"key":"e_1_2_9_101_1","unstructured":"JonesA O'GormanC LiptonRB TepperSJ TabuteauH.Efficacy and safety of AXS\u201007 (MoSEIC meloxicam\/rizatriptan) in the acute treatment of migraine: results from MOMENTUM phase 3 trial. Presented at the 72nd American Academy of Neurology Annual Meeting; September 23 2020; Virtual."},{"key":"e_1_2_9_102_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001801"},{"key":"e_1_2_9_103_1","unstructured":"Axsome Therapeutics Inc.SYMBRAVO (Meloxicam and Rizatriptan) Highlights of Prescribing Information;2025. Accessed February 13 2025.https:\/\/www.axsome.com\/wp\u2010content\/uploads\/2025\/02\/SYM\u2010USPI\u2010001.001\u201020250224.pdf"},{"key":"e_1_2_9_104_1","unstructured":"NicolasS NicolasD.Triptans;2023. Accessed December 12 2024.https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32119394"},{"key":"e_1_2_9_105_1","unstructured":"Cleveland Clinic.Triptans;2023. Accessed April 19 2024.https:\/\/my.clevelandclinic.org\/health\/treatments\/24998\u2010triptans"},{"key":"e_1_2_9_106_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12601"},{"key":"e_1_2_9_107_1","unstructured":"Boehringer Ingelheim Pharmaceuticals I.Mobic\u00ae (Meloxicam) Tablets Highlights of Prescribing Information;2012. Accessed December 12 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020938s022lbl.pdf"},{"key":"e_1_2_9_108_1","doi-asserted-by":"publisher","DOI":"10.4103\/joacp.JOACP_133_18"},{"key":"e_1_2_9_109_1","unstructured":"O'GormanC JonesA TabuteauH.AXS\u201007 (MoSEIC Meloxicam\/Rizatriptan): Novel Oral Therapeutic in Clinical Development for the Acute Management of Migraine. Presented at the 19th Congress of the International Headache Society; September 5\u20138 2019; Dublin Ireland."}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.70051","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.70051","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.70051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:42:26Z","timestamp":1786632146000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.70051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":108,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/head.70051"],"URL":"https:\/\/doi.org\/10.1111\/head.70051","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"2025-08-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}